2232. Eliminating HCV co-infection in HIV: A Positive Health Clinic (PHC) Venture
Session: Poster Abstract Session: HIV and HCV
Saturday, October 7, 2017
Room: Poster Hall CD
Posters
  • AGH-IDSA HIV HCV Coinfection poster absolute final.pdf (517.2 kB)
  • Background: HCV/HIV co-infected patients have a higher risk of liver disease progression and mortality despite highly effective ART. Near 100% cure rate for HCV infection can be achieved by current direct-acting agents (DAA) against HCV. Therefore, treatment for all patients with HCV/HIV has been recommended by IDSA/AASLD.

    Setting: PHC is a Ryan White Care Act funded HIV outpatient clinic providing care for approximately 900 patients in Pittsburgh, PA.

    Methods: At our clinic, a quality improvement project incorporating treatment algorithms targeting HCV/HIV was established for providers to guide HCV therapy.

    Results: From 1/1/2014 – 4/30/2017, a total of 71 (12 F 59 M; 35 AA/1 H/35 W; Risk: 38 IVDU/31 MSM) HCV/HIV co-infections were identified (GT1: 57; GT3: 6; GT4: 1) with median age of 52 years (range: 21-73). Among them, 21 had fibrosure scores ≥ 3 and 22 <2. Out of 43 patients, 38 completed DAA (test of cure: 34) and 5 are currently on therapy. Lengths of treatment were 8 weeks (4), 12 weeks (30), 16 weeks (1) and 24 weeks (3). All patients had undetectable HCV viral loads at end of treatment (EOT) and test of cure (TOC) visits. Owing to our clinic staff members’ persistent efforts, 5 patients remained adherent to therapy despite having medical events requiring inpatient admission. One patient skipped 7 days of therapy (D22-D28) but still achieved undetectable levels at the EOT and TOC.

    Among those who had not received DAA (28), 5 died (AIDS:1, Malignancy:2, ESRD:2, Liver disease:1), 3 patients cleared the HCV virus without DAA; 4 Incarcerated; and 3 lost to care. Other barriers to therapy included Fibrosure <2 (preceding 2/1/2017), metastatic cancer, noncompliance and neuropsychiatric illness.

    Conclusion: With DAAs, HCV co-infection rate at our PHC has decreased from 8% to 1.5%, anticipating further decrease to 0.5%. In our cohort, there were four HCV/HIV with GT1a were successfully treated with 8 weeks’ course. This is not currently endorsed by the IDSA/AASLD guidelines for the co-infected population, however. Appropriate DAA HCV/HIV therapy coupled with intensive counseling and monitoring can possibly achieve 100% cure rate and elimination of HCV infection in HIV.

    Arpan Shah, M.D1, Cindy Magrini, PharmD2, Lori Mezeivtch, PharmD3 and Chiu-Bin Hsiao, MD, FIDSA, AAHIVS1,4, (1)Infectious Disease, Allegheny General Hospital/Allegheny Health Network, Pittsburgh, PA, (2)Positive Health Clinic, Allegheny Health Network, Pittsburgh, PA, (3)Coordinate Care Network, Pittsburgh, PA, (4)The Positive Health Clinic, Allegheny Health Network, Pittsburgh, PA

    Disclosures:

    A. Shah, None

    C. Magrini, None

    L. Mezeivtch, None

    C. B. Hsiao, MERCK: Investigator , Research grant
    GILEAD: Investigator , Research grant
    VIIV: Investigator , Research grant
    GILEAD: Scientific Advisor , Consulting fee

    See more of: HIV and HCV
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.